NasdaqCM - Nasdaq Real Time Price USD

GeoVax Labs, Inc. (GOVXW)

0.0302

-0.0031

(-9.31%)

At close: April 22 at 4:00:00 PM EDT

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities ATLANTA, GA - April 22, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunot...

NewMediaWire 19 hours ago

GOVX

GOVXW
-9.31%
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology compan...

NewMediaWire 6 days ago

GOVX

GOVXW
-9.31%
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BARDA-funded Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine, the firm says. This decision, made for the government’s convenience, halts a pivotal study that was set to evaluate GEO-CM04S1 against an approved mRNA vaccine in a 10,000-participant trial under Project NextGen. The abru

TipRanks 6 days ago

GOVX

GOVXW
-9.31%
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

Company Reaffirms Commitment to Innovation in COVID-19, Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing va...

NewMediaWire 6 days ago

GOVX

GOVXW
-9.31%
Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index shedding 0.7% and

PREMIUM
MT Newswires 7 days ago

GOVXW
-9.31%
GeoVax to Present at the Emerging Growth Conference on April 16, 2025

Company to Provide an Update on Its GEO-CM04S1 Program,Including the Recent BARDA Contract Termination ATLANTA, GA - April 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines ag...

NewMediaWire 7 days ago

GOVX

GOVXW
-9.31%
GeoVax to Present Clinical Data at Upcoming April Industry Events

Data to be Presented on the Company's GEO-CM04S1 and Gedeptin Programs ATLANTA, GA - April 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dise...

NewMediaWire 7 days ago

GOVX

GOVXW
-9.31%
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent

Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio ATLANTA, GA - April 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and inf...

NewMediaWire 13 days ago

GOVX

GOVXW
-9.31%
Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Geovax Labs Inc (GOVX) secures a $400 million award for COVID-19 vaccine development while navigating financial hurdles and global partnerships.

GuruFocus.com 26 days ago

GOVXW
-9.31%
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed Additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in...

NewMediaWire 26 days ago

GOVX

GOVXW
-9.31%
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire 28 days ago

GOVX

GOVXW
-9.31%
PLAB
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ATLANTA, GA - March 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a securiti...

NewMediaWire 29 days ago

GOVX

GOVXW
-9.31%
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA - March 17, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today ...

NewMediaWire last month

GOVX

GOVXW
-9.31%
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK

Hub to Advance Global Vaccine and Immuno-Oncology Development ATLANTA, GA - March 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in the development of immunotherapies and vaccines, toda...

NewMediaWire last month

GOVX

GOVXW
-9.31%
GeoVax to Present at the 37th Annual Roth Conference

ATLANTA, GA - March 11, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will prese...

NewMediaWire last month

GOVX

GOVXW
-9.31%
Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2. The Democratic Republic of the Congo (DRC) is the epicenter, with over 60,000 suspected cases and 1,300 deaths in 2024 al...

NewMediaWire last month

GOVX

GOVXW
-9.31%
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy

GeoVax's GEO-MVA: Strengthening U.S. Biodefense ATLANTA, GA - March 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing vaccines and immunotherapies for infectious diseases and cancer, underscores the strategic importanc...

NewMediaWire last month

GOVX

GOVXW
-9.31%
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

GeoVax Advancing GEO-MVA Vaccine Candidate to Bolster Global Supply Options ATLANTA, GA - February 27, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX) commented on today's statement from The World Health Organization (WHO) concerning Mpox. In ...

NewMediaWire last month

GOVX

GOVXW
-9.31%
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations ATLANTA, GA - February 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOV...

NewMediaWire last month

GOVX

GOVXW
-9.31%
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification

GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York underscores the urgent need for a stronger and more diversified vaccine sup...

NewMediaWire 2 months ago

GOVX

GOVXW
-9.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GeoVax Labs, Inc. (GOVXW)

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

Sector Update: Health Care Stocks Retreat Late Afternoon

GeoVax to Present at the Emerging Growth Conference on April 16, 2025

GeoVax to Present Clinical Data at Upcoming April Industry Events

GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent

Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GeoVax Reports 2024 Year-End Financial Results and Provides Business Update

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK

GeoVax to Present at the 37th Annual Roth Conference

Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy

GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification